Sucampo Pharmaceuticals — Investor Presentation (May 2014)
25 slides from Sucampo Pharmaceuticals's investor presentation, May 19, 2014
Slide 1: Sucampo presenters
Peter Greenleaf Chief Executive Officer Cary Claiborne Chief Financial Officer Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications e 3 SUCAMPO The Science of innovation
Slide 2: Agenda
Agenda Introductions and Forward-Looking Statements Leadership Update Company Introduction & Value Proposition Prostone Platform Technology Overview Commercial Overview Pipeline and Product Development Guidance Key Upcoming Events Conclusion PANO PS is The Sucampo logo and the tagline, The Science o
Slide 3: Forward-looking statements
This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set fo
Slide 4: Sucampo Leadership Update
Sucampo Leadership Update Peter Greenleaf, Chief Executive Officer 20 years of biopharmaceutical experience in commercialization, strategic planning & drug development Former CEO and Director of Histogenics Former President of Medimmune, the worldwide biologics R&D arm of AstraZeneca Board Member: B
Slide 5: Sucampo Value Proposition: Commercial-Stage, Global Biopharmaceutical Company
Sucampo Value Proposition: Commercial-Stage, Global Biopharmaceutical“Gompany + Entrepreneurial Great People * Passionate + Lean and Nimble Organization OOOO ee eee + Proprietary Prostone Technology + 2Approved Products Great Science + AMITIZA® (lubiprostone) in gastroenterology + RESCULA® (unoprost
Slide 6: Has generated two globally approved products
Has generated two globally approved products * AMITIZA ®, RESCULA ® What are prostones? + Functional fatty acids naturally occuring in the human body * lon-channel activators + Physiological mediators of restoration of cellular sae 7 homeostasis and tissue regeneration ohh Sa Barrier Repair and Muco
Slide 7: AMITIZA U.S.
AMITIZA U.S. Continued AMITIZA YOY Growth + Net sales growth of 16% for Q1 2014 compared to Q1 2013 + TRx growth of 3% for Q17 Market Growth Accelerating * Class up 6% for Q1 2014 vs. Q1 2013 Strong Partner Commercial Execution Driving Sales Growth * Over 8M TRx’s in = 8 years; heritage is driver of
Slide 8: Global AMITIZA Approvals and Regulatory Filings
Global AMITIZA Approvals_and Regulatory Filings Switzerland CIC (2009) CIC (2012) OIC Update Japan CC (2012) Incl OIC US. CIC (2006) IBS-C (2008) OIC Approved (April 2013) $ sucampo 8 The Science of innovation
Slide 9: AMITIZA Global Snapshot
AMITIZA Global Snapshot Japan * Continued success; sales continue to be above our and Abbott's expectations + AMITIZA sales in Japan Europe Switzerland * OIC decision = 2H 2014 * Several reimbursement limitations revised Rest of World * Continued partnership discussions with global and regional comp
Slide 10: AMITIZA Intellectual Property
AMITIZA Intellectual Property AMITIZA has a robust U.S. patent estate * 13 patents in Orange Book; latest patents expire in 2027 Paragraph IV certification notice letter to Sucampo: January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals + Notice letter alleges claims in AMITIZA’s
Slide 11: RESCULA U.S. Overview
RESCULA U.S. Overview + RESCULA Commercial Strategy + Implemented new commercial strategy for RESCULA * Reducing investment in product + Focus on current RESCULA prescribers + Contract sales representatives are spending 20% of time calling on current RESCULA prescribers * Belief in value of continue
Slide 12: At-A-Glance: Sucampo Pipeline
At-A-Glance: Sucampo Pipeline CLINICAL FOCUS LEAD COMPOUNDS STAGE OF CLINICAL DEVELOPMENT PRECLINICAL | PHASE1 PHASE2 PHASE 3 Lubiprostone Pediatric Functional Constipation Began Q4 13 TTT EE EE ee | Lubiprostone Alternate Formulation CIC Began Q3 13 PE EE Unoprostone Isopropyl Retinitis Pigmentosa*
Slide 13: Lubiprostone Clinical Development
Lubiprostone Clinical Development Pediatric Functional Constipation (PFC) * Prevalence: = 4 - 37% of children worldwide have functional constipation* + Initiated global pivotal P3 clinical program for lubiprostone for children and adolescents aged 6 - 17 years with PFC + First patients enrolled into
Slide 14: Unoprostone Isopropyl for Retinal Disease
Unoprostone Isopropyl for Retinal Disease Retinitis Pigmentosa (RP) * Prevalence: =1 in 4,000 individuals WW suffer from RP + Degenerative retinal disease with no approved prescription medicines available® * Ongoing P3 clinical trial by development partner, R-Tech Ueno + Interim 1 yr results availab
Slide 15: Key Facts, Financial Highlights & Guidance
ey Facts, Financial Highlights_&-Guidance Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD | Stock Price (05-14-14), 52-Week Range | $6.80; $11.00 to $5. 40 | | Shares Outstanding (05-14-14) 44.5M (1 class of common stock) | Daily Volume (90-day average) 237.252 | | Market Capitaliza
Slide 16: Upcoming Events
Upcoming Events Commercial AMITIZA OIC indication potential approval in Switzerland AMITIZA NICE endorsement potential in the U.K. Clinical Beginning phase 2a trial of cobiprostone in oral mucositis Conclusion in Q3 2014 of phase 1b trial of orally administered ion-channel activator for lumbar spina
Slide 17: Sucampo Value Proposition: Commercial-Stage, Global Biopharmaceutical Company
Sucampo Value Proposition: Commercial-Stage, Global Biopharmaceutical“Gompany + Entrepreneurial Great People * Passionate + Lean and Nimble Organization OOOO ee eee + Proprietary Prostone Technology + 2Approved Products Great Science + AMITIZA® (lubiprostone) in gastroenterology + RESCULA® (unoprost
Slide 18: $ suCAMPO
€ , $ suCAMPO The Science of innovation
Slide 19: Trading Symbol SCMP (NASDAQ) key facts
TradingSymbol SCMP (NASDAQ) Debt = 2M Corporate Headquarters Bethesda, MD Cash & Equivalents $106.0M Stock Price (05-14-14), $6.80, $11.00 to Total OperatingExpense | $16.0M eae Range | LE s50 Total Revenue $22.2M Shares Outstanding 44.5M (1 (1 class of (05-14-14) corimtn stack) Net Income $0.7M Dai
Slide 20: Sucampo Prostone Pipeline Key Highlights
Sucampo Prostone Pipeline Key Highlights Cobiprostone for Oral Mucositis Oral Mucositis + Prevalence: ~350,000 head and neck cancer patients in the U.S." oral mucositis affects 80-90%'2 of these patients Formation of ulcers that result from radiation therapy and chemotherapy in cancer patients * Tot
Slide 21: Terms of Sucampo's AMITIZA Agreements
Terms of Sucampo’s AMITIZA Agreements Takeda Agreement * Takeda shall promote, market, and sell AMITIZA in U.S. and Canada + Sucampo's tiered royalty rate: 18%-26% of annual net sales + Sucampo earned $20M in upfront and $140M in development milestone payments as of 3/31/14 + Sucampo received $117M
Slide 22: Issued Lubiprostone U.S. Patents
Issued Lubiprostone U:S. Patents No. Type of Patent 284, 858" 2014 Composition of matter (drug substance) 6,414,016" 2020 Therapeutic use (treating constipation) 6,583,174" 2020 ‘Composition of matter (drug product) 6,982,283" 2022 Therapeutic use (treating OIC) 7,064,148" 2022 Therapeutic use (trea
Slide 23: Issued Patents: Lubiprostone Ex U.S.
ued Patents Lubiprostone Ex U.S. pO a 4220316 2023 Compostionofmater rug susetance ander rogue) 4300353 2025 Therapeutcuse (reatng O10) 460488 208 Therapauicuse reatng constipation) 4783794 2028 Composton of mater rus produ) 4786806 228 Therapeuc use (eatng constipation) 4952228 2023 Therapeutic use
Slide 24: Additional Issued Patents
Additional Issued Patents. Unoprostone 5773471 2016 Therapeuticuse (treating retinitis pigmentosa) 8.770675" 2018 Compostion ofmatter drug product and therapeuticuse (treating ocularhypertension) 6.450.896" 2024 Therapeuticuse (veating ocular hypertension and glaucoma) 0,609,729 2034 Therapeuticuse
Slide 25: References
References IMS Smart View, NPA Report, client Factored Numbers Internal Research Fingertip Formulary (NOV 2013) Camilleri tt Opioid.induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011 May;106(5):835-42 Radiograph from Borowitz - Pediatric Constipation article on M
Sucampo Pharmaceuticals — Investor Presentation (May 2014) on 6ix